Stock Market Update - November 26, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. SMX - SMX (Security Matters) Public Limited Company
Price: $17.4 | Change: +194.42% ($11.49)
SMX (Security Matters) shareholders enjoyed an astonishing 194.42% gain following the company's prominent presence at the DMCC Precious Metals Conference in Dubai. The excitement stemmed from SMX showcasing its patented molecular-marking technology, which embeds unique, indelible molecular identities into physical materials. This innovation links items to a secure digital record for enhanced traceability and authenticity, even surviving processes like melting and recasting.
Crucially, SMX also revealed it had secured and deployed six strategic partnerships throughout 2025, including a significant collaboration with Goldstrom. This partnership integrates SMX’s molecular markers and digital registry infrastructure into Goldstrom's global network. This move is seen as a major architectural shift, pushing the precious metals industry towards scientifically verified transactions rather than relying solely on trust, which ignited strong investor confidence.
2. KTTA - Pasithea Therapeutics Corp.
Price: $1.06 | Change: +117.39% ($0.5724)
KTTA just surged an impressive 117.39%! Pasithea Therapeutics Corp. is experiencing this significant rise thanks to a flurry of positive news surrounding its lead drug candidate, PAS-004, and a crucial new grant.
The company recently secured a $1 million grant from the ALS Association to fund the first clinical trial for PAS-004 in patients with Amyotrophic Lateral Sclerosis (ALS). This major funding arrived alongside several encouraging updates from its Phase 1 trial for PAS-004 in advanced cancer patients, which showed favorable interim data, including a partial response in a melanoma patient and a good safety profile.
These clinical breakthroughs, particularly the new ALS funding and positive trial results, are proving to be powerful catalysts for investor confidence. This is notable as these developments are helping to boost sentiment despite the company's earlier Q3 financial results that highlighted ongoing losses and liquidity challenges.
3. ZYXI - Zynex, Inc.
Price: $1.59 | Change: +115.62% ($0.8526)
ZYXI just rocketed up 115.62% following a dramatic rebound. This medical technology company saw its stock plunge over 50% after reporting a very disappointing third-quarter earnings report. They announced a significant drop in revenue and a hefty net loss, primarily due to payment suspensions and changes in insurance practices.
However, the tide turned quickly. The stock experienced a strong technical bounce from a new low point, which analysts refer to as a "pivot bottom," attracting renewed interest. This recovery was further fueled by significant pre-market jumps, algorithmic trading, and positive trends seen across the broader biotech sector.
What makes ZYXI's recent surge particularly interesting is how the company's earlier announcement of exploring strategic alternatives, like capital raising or restructuring, and appointing a new board member to oversee these changes, might have supported investor confidence in a potential turnaround following the initial negative reaction to its earnings.
4. AMBR - Amber International Holding Ltd
Price: $2.47 | Change: +56.33% ($0.89)
AMBR soared with a remarkable 56.33% gain following the release of its strong third-quarter 2025 financial results and the announcement of a substantial share repurchase program around November 27, 2025. This digital wealth management platform delivered some compelling news that caught investors' attention.
Amber International reported a significant turnaround, shifting from a previous loss to a positive 8% operating profit margin and achieving a net income of $2.2 million. Client assets on their platform also saw impressive growth, climbing by 69.8% year-over-year to $1.84 billion. The additional news of a $50 million share repurchase program, set to begin in December, further signaled strong management confidence in the company's future business momentum and long-term growth.
5. KALA - KALA BIO, Inc.
Price: $0.9104 | Change: +42.63% ($0.2721)
KALA just surged an impressive 42.63%, driven by a comprehensive rescue financing agreement and a critical loan settlement around late November 2025. These moves effectively averted an impending asset seizure and injected much-needed capital into the company.
KALA BIO announced a multi-stage financing deal designed to bring in up to $6 million, with an initial $1.8 million already secured. Concurrently, the company settled a significant loan with its lender, Oxford, reducing its debt by $7 million and resolving all outstanding obligations. Adding to the positive sentiment, David Lazar, known for turning around distressed companies, was appointed CEO and is personally investing $6 million in KALA, with $1.8 million already contributed.
These developments mark a crucial turning point for KALA BIO. This fresh momentum comes after the company experienced a major stock decline in September 2025 following the failure of its eye disease therapy in a Phase 2 trial. Investors appear to be responding positively to the new leadership and financial restructuring, seeing it as a potential fresh start.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.